
- /
- Supported exchanges
- / US
- / GNPX.NASDAQ
Genprex Inc (GNPX NASDAQ) stock market data APIs
Genprex Inc Financial Data Overview
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patient populations with unmet medical needs. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. The company's lead product candidate, Reqorsa gene therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials for the treatment of non-small cell lung cancer and small cell lung cancer. It is also developing diabetes gene therapy, a novel infusion process that uses an adeno-associated virus vector to deliver Pdx1 and MafA genes directly to the pancreas; GPX-002 for Type 1 diabetes transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Genprex Inc data using free add-ons & libraries
Get Genprex Inc Fundamental Data
Genprex Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -21 167 474
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: -2.54
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Genprex Inc News

Genprex files to sell 15M shares of common stock for holders
* Genprex (NASDAQ:GNPX [https://seekingalpha.com/symbol/GNPX]) filed to sell 15M shares of common stock for holders. * Filing [https://seekingalpha.com/filing/10091074] MORE ON GENPREX * Financial information for Genprex [https://seekingalpha.com/symbol/GNPX/income-statement]


Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire — Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted b...

4 big analyst cuts: Premier downgraded at Piper Sandler following Q4 earnings
Here is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades at Premier, Workday, Genpact, and Genprex. InvestingPro subscribers got this news first. Never miss ...

Genprex Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China
LOS ANGELES, CA - (NewMediaWire) - July 28, 2023 - (InvestorBrandNetwork via NewMediaWire) - IBN, a multifaceted financial news, content creation and publishing company, is utilized by both public and...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.